Sökning: onr:"swepub:oai:DiVA.org:mdh-62344" >
Patient Perspective...
-
Schölin Bywall, KarinUppsala universitet,Centrum för forsknings- och bioetik
(författare)
Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making : A Qualitative Study in Swedish Patients with Rheumatoid Arthritis
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
2018-11-15
-
Springer Science and Business Media LLC,2019
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:mdh-62344
-
https://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-62344URI
-
https://doi.org/10.1007/s40271-018-0344-2DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-366354URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BackgroundThere is increasing interest in involving patient preferences for benefits and risks in regulatory decision making. Therefore, it is essential to identify patient perspectives regarding the value of patient preference information (PPI).ObjectivesThe aim of this study was to explore how patients with rheumatoid arthritis (RA) value the use of PPI in regulatory decision making regarding medical products.MethodsRegulators and patients with RA were interviewed to gather initial insights into opinions on the use of PPI in regulatory decisions regarding medical products. The interviews were used to draft and validate the interview guide for focus groups with patients with RA. Participants were purposively sampled in collaboration with the Swedish Rheumatism Association in Stockholm and Uppsala. Each focus group consisted of three to six patients (18 in total). All interviews were audio-recorded, transcribed verbatim, and analysed using content analysis.ResultsAccording to the participants, PPI could lead to regulators considering patients’ needs, lifestyles and well-being when making decisions. PPI was important in all stages of the medical product lifecycle. Participants reported that, when participating in a preference study, it is important to be well-informed about the use of the study and the development, components, administration, and risks related to the medical products.ConclusionsPatients thought PPI could be valuable to consider in regulatory decisions. It is essential for patients to be well-informed when asked for their preferences. Research on information materials to inform patients in preference studies is needed to increase the value of PPI in regulatory decision making.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Veldwijk, JorienUppsala universitet,Centrum för forsknings- och bioetik,Erasmus School of Health Policy & Management (ESHPM) and Erasmus Choice Modelling Centre (ECMC), Erasmus University Rotterdam, Rotterdam, The Netherlands(Swepub:uu)jorve818
(författare)
-
Hansson, Mats G.,1952-Uppsala universitet,Centrum för forsknings- och bioetik(Swepub:uu)matshans
(författare)
-
Kihlbom, Ulrik,1961-Uppsala universitet,Centrum för forsknings- och bioetik(Swepub:uu)ulkih227
(författare)
-
Uppsala universitetCentrum för forsknings- och bioetik
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Patient: Springer Science and Business Media LLC12:3, s. 297-3051178-16531178-1661
Internetlänk
Hitta via bibliotek
-
Patient
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas